Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kylo-0603 in MASLD
NCT07878091Phase 2Not yet recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Nov 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of kylo-0603 in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Chia Tai Tianqing. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
kylo-0603
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07878091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07878091.